China’s First Biotech Refinancing Deals in 2022 To Raise $712m

 
• By Dexter Jie Yan
  
fund raising
deals are first such attempt by Chinese biotechs to raise post-STAR Market IPO funds • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia